PT - JOURNAL ARTICLE AU - Janelidze, Shorena AU - Stomrud, Erik AU - Smith, Ruben AU - Palmqvist, Sebastian AU - Mattsson, Niklas AU - Airey, David C. AU - Proctor, Nicholas K. AU - Chai, Xiyun AU - Shcherbinin, Sergey AU - Sims, John R. AU - Dage, Jeffrey L. AU - Hansson, Oskar TI - Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease AID - 10.1101/2020.01.15.20017236 DP - 2020 Jan 01 TA - medRxiv PG - 2020.01.15.20017236 4099 - http://medrxiv.org/content/early/2020/01/16/2020.01.15.20017236.short 4100 - http://medrxiv.org/content/early/2020/01/16/2020.01.15.20017236.full AB - Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD) reflecting abnormal tau metabolism in the brain. Tau can be phosphorylated at multiple other sites including threonine 217, and here we investigated the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFINDER cohort (n=194), p-tau217 had stronger correlations with the tau PET tracer [18F]flortaucipir, and more accurately identified individuals with abnormally increased [18F]flortaucipir retention. Furthermore, longitudinal increases in p-tau217 were higher compared to p-tau181 and better correlated with [18F]flortaucipir retention. P-tau217 correlated better than p-tau181 with PET measures of neocortical amyloid-β burden and more accurately distinguished AD dementia from non-AD neurodegenerative disorders. Higher correlations between p-tau217 and [18F]flortaucipir were corroborated in an independent EXPEDITION3 trial cohort (n=32). These findings suggest that p-tau217 might be more useful than p-tau181 in the diagnostic work up of AD.Competing Interest StatementSJ, ES, SP, NM report no disclosures. RS has served as a non-paid consultant for Roche. OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. JLD, NKP, XC, DCA, JRS, SS are employees of Eli Lilly and Company.Funding StatementThe study was supported by the European Research Council, the Swedish Research Council, the Knut and Alice Wallenberg foundation, the Marianne and Marcus Wallenberg foundation, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, The Parkinson foundation of Sweden, the Skåne University Hospital Foundation, and the Swedish federal government under the ALF agreement. The funding sources had no role in the design and conduct of the study; in the collection, analysis, interpretation of the data; or in the preparation, review, or approval of the manuscript. Doses of [18F]flutemetamol injection were sponsored by GE Healthcare and the precursor of [18F]Flortaucipir was provided by AVID Radiopharmaceuticals. Euroimmun Aβ42, Aβ40 and T-tau kits were provided by Euroimmun. Analysis of p-tau217 and p-tau181 were performed at Eli Lilly and Company. We thank Dr. Wenling Zhang at Eli Lilly and Company for help with SAS statistical analysis.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data will be shared by request from any qualified investigator for the sole purpose of replicating procedures and results presented in the manuscript and as long as data transfer is in agreement with EU legislation on the general data protection regulation (GDPR).